About Premie BiliRecs

About

Premie BiliRecs (PBR) was created to provide clinical decision support for treatment of indirect hyperbilirubinemia in pre-term neonates from 27 weeks and 0 days through 34 weeks and 6 days post-menstrual age. Though there is a dearth of evidence on phototherapy and exchange transfusion thresholds for this age group, PBR serves to operationalize the expert recommendations published by Maisels et al. in 2012. Because phototherapy and exchange transfusion thresholds are lower at early postnatal age, the tool is intended for use in infants greater than 48 hours of age. Ultimately, expert clinical reasoning should guide management of indirect hyperbilirubinemia in preterm neonates of any postnatal age.

References

Peer-reviewed journal articles:

An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation
Maisels MJ, Watchko JF, Bhutani VK, and Stevenson DK
Journal of Perinatology June 2012

Jaundice and kernicterus in the moderately preterm infant
Wallenstein MW, Bhutani VK
Clinics in Perinatology December 2013

Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
AAP Subcommittee on Hyperbilirubinemia
Pediatrics July 2004

Created By

Clinical Assistant Professor, Neonatal and Developmental Medicine Stanford University
Neonatology Fellow Stanford University
Senior Application Engineer Stanford Children's Health
Professor of Pediatrics, Neonatal and Developmental Medicine Stanford University